Evogene Ltd.

Ladies and gentlemen, thank you for standing by. Welcome to Evogen's first quarter 2023 results conference call. All participants are present in listen-only mode. On management's formal presentation, instructions will be given for the question and answer session. For operator assistance during the conference, please press star zero. As a reminder, this conference is being recorded May 18th, 2023. Before we begin, I would like to caution that certain statements made during this earnings conference call by Evogen's management will constitute forward-looking statements that relate to future events, risks, and uncertainties regarding business, strategy, operations, and future performance and results of Evogen. I encourage you to review Evogen's filings with the U.S. Securities and Exchange Commission and read the note regarding forward-looking statements in today's earnings release, which states that statements made in the earnings release and in a similar way on this earnings conference call that are not historical facts may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For example, Evagen is using forward-looking statement in this call when it discusses the results of Biomica's Phase I clinical trial for its immuno-oncology microbiome drug candidate. BMC 333's progress to Phase I clinical trials, BMC 426's advance in its preclinical trials, Labibio's expansion of sales into Canadian and European markets, an introduction of new crops like small grains and oilseeds, registration of Labibio's biofungicide for fruit rots and powdery mildews with the U.S. EPA, and LAV321's further field trials, potential collaboration of AgPlanus with respect to its APH1 candidates, Achievement of first milestone in AgPlanus' collaboration with Corteva. The nomination of new protein targets and achievement of greenhouse readout in its wheat blotch fungicide program. Canonic's goal to expand second-generation product sales and receipt of royalty payments from variety licensing. Corteva's territorial expansion and increased sales. The potential commercial value of the product of the AgSeed Division's grant program. All forward-looking statements made herein speak only as of the date of the announcement of results. Many of the factors that impact whether forward-looking statements will come true are beyond the control of Evogen and may cause actual results to differ materially from anticipated results. Evogen is under no obligation to update publicly or alter our forward-looking statements, whether as a result of new information, future events, or otherwise, except as otherwise required by law. We expressly disclaim any obligation to do so. More detailed information about the risk factors potentially adversely impacting our performance can be found in our report filed with the U.S. Securities and Exchange Commission. That said, I would now like to turn over the call to Rachel Pomeran, Evergen's Head of Investor Relations. Rachel, please go ahead.

Welcome to Evergen's earnings call in the first quarter of 2023, and thank you all for joining us. My name is Rachel, and I'm the new investor relations director at Evogen. I'm excited to join this innovative team and help drive growth through solid investor relationships and effective communication. Starting the call today is the president and CEO of Evogen, Ofer Khabib, who will provide insight into our business model and the significance of our technological engines and the life science industry. He will also provide updates on Evogen subsidiaries. Also joining offer on today's call are Dr. Nir Harbel, Evogen's Chief Product Officer, who will be discussing some of the recent improvements we have made to Evogen's AI tech engines. Dr. Elran Haber, the CEO of Biomica, Evogen's subsidiary, focusing on developing drugs based on the human microbiome, will follow offer's review and elaborate on Biomica's activity and achievements. Our CFO, Yaron Eldad, will later provide a financial summary and update. But first, it is my pleasure to introduce our main speaker, the President and CEO of Evogen, Ofer Haviv.

Thank you, Rachel, and good day, everyone. Today, I will review Evogen's activities and recent accomplishments and provide you with an update on potential catalysts expected in the near future. I will also discuss some of our subsidiaries' recent accomplishments, leveraging our technology and demonstrating the power of the value of our AI-driven tech engines underlying the product development process. As you know, Avogen has been using its computational predictive biology platform, the CPB, to direct and accelerate the discovery and development of life science-based products. The CPB is the foundation of our three tech engines. Microboost AI supports the discovery and development of microbe-based products. Campus AI supports small molecule-based products. And Generator AI supports products based on genetic elements. Our AI-driven tech engine has addressed the main challenge in life science-based product development. finding the winning candidate or candidates out of that number of possible prospects that addresses a complex myriad of criteria to reach successful commercial products. Many potential candidates exist when identifying a specific microbe, gene, or small molecule. Our AI tech engines help to find that needles in high tech in a way and within a time frame and cost that our competitors or partners may not be able to accomplish, and most importantly, increase the probability of success. Around each of our three tech engines, Evergent has established a business ecosystem, including independent subsidiaries or strategic collaborations. This focuses on developing products for a specific lifetime market segment, benefiting from the tech engines as their main competitive advantage. I am pleased to introduce Dr. Nir Arbel, Avogen's Chief Product Officer, who is leading the development of our AI tech engine, to share with you more information and the latest AI tech engine development accomplishment. Nir?